To further examine the concept that CXCR2 antagonism sensitises NASH-HCC to anti-PD1 therapy we asked if combination therapy activates classic T-cell mediated anti-tumour immunity. The gene discussed is CXCR2; the disease is hepatocellular carcinoma.